Chemomab Receives New Patents For Nebokitug, A First-In-Class Drug Aiming To Treat Primary Sclerosing Cholangitis

Chemomab Therapeutics, Ltd., a clinical-stage biotechnology company focused on developing treatments for fibro-inflammatory diseases, has announced that its lead product, nebokitug (formerly known as CM-101), has received new patent protections in China and Russia.

In China, the State Intellectual Property Office has granted Patent No. ZL 2018 8 0018207.8, titled “Anti-CCL24 (Eotaxin 2) Antibodies for Use in the Treatment of Hepatic Disease”. This patent secures the use of nebokitug in treating hepatic conditions, including primary sclerosing cholangitis, and will remain in effect until 2038. In Russia, the Federal Service for Intellectual Property has issued Patent No. 2022125176, titled “A Method of Treatment Using Anti-CCL24 Antibodies”. This patent protects various formulations and dosing regimens of nebokitug, offering extended coverage through 2041.

Adi Mor, PhD, co-founder and Chief Executive Officer of Chemomab, said in a statement, “These newly granted patents further strengthen the company’s extensive intellectual property portfolio for nebokitug, reinforcing its leading strategic position in primary sclerosing cholangitis (PSC) established by the positive data from the nebokitug Phase 2 SPRING trial, which we believe represents the most promising clinical results to date in this debilitating and potentially lethal disease that lacks effective treatment.”

He further added, “Furthermore, for the first time the FDA has aligned on a clear and straightforward pathway to regulatory approval in PSC. We have amassed a large and comprehensive intellectual property portfolio for nebokitug and are pleased to add these new patents in China and Russia, two significant territories for future commercialization. Enlarging the scope of our patent protections is especially relevant as we continue to advance potential partnerships to support a nebokitug Phase 3 registrational trial in PSC.”

These new patents further strengthen Chemomab’s intellectual property portfolio and support the continued development and commercialization of nebokitug. By securing long-term protections in two additional international markets, the company reinforces its strategic position in advancing therapies for serious liver-related and inflammatory diseases with limited treatment options.